These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30347271)

  • 21. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
    Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S
    Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure.
    Nishihara Y; Nishimori M; Sawa T; Uemura K; Nagai S; Todo S; Oota E; Odajima S; Takeuchi K; Ichikawa Y; Kintsu M; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Shimizu M; Hirata KI; Tanaka H
    Heart Vessels; 2024 Feb; 39(2):95-104. PubMed ID: 37733071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test.
    Malfatto G; Ravaro S; Caravita S; Baratto C; Sorropago A; Giglio A; Tomaselli M; Parati G; Villani A
    Acta Cardiol; 2020 Dec; 75(8):732-736. PubMed ID: 31577528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
    Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study.
    Carluccio E; Dini FL; Bitto R; Ciccarelli M; Correale M; D'Agostino A; Dattilo G; Ferretti M; Grelli A; Guida S; Jacoangeli F; Lupi L; Luschi L; Masarone D; Mercurio V; Pacileo G; Pugliese NR; Rispoli A; Scelsi L; Tocchetti CG; Brunetti ND; Palazzuoli A; Piepoli M; Nodari S; Ambrosio G;
    Int J Cardiol; 2022 Mar; 350():62-68. PubMed ID: 34998946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.
    Liu S; Wang Y; Lu S; Hu J; Zeng X; Liu W; Wang Y; Wang Z
    Life Sci; 2021 Feb; 266():118877. PubMed ID: 33310048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.
    Vaskova E; Ikeda G; Tada Y; Wahlquist C; Mercola M; Yang PC
    J Am Heart Assoc; 2020 Jul; 9(13):e015640. PubMed ID: 32538237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
    Tersalvi G; Dauw J; Martens P; Mullens W
    Curr Heart Fail Rep; 2020 Aug; 17(4):145-152. PubMed ID: 32488503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Chrysant SG
    J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction.
    Vergaro G; Del Franco A; Carecci A; Ferrari Chen YF; Aimo A; Forini F; Nicolini G; Kusmic C; Faita F; Castiglione V; De Tata V; Pucci A; Musetti V; Burchielli S; Passino C; Emdin M
    Int J Cardiol; 2024 Aug; 409():132203. PubMed ID: 38795973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
    Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.